Efficacy Parecoxib and Ketorolac as Preemptive Analgesia in Spine Fusion

Prince of Songkla University96 enrolled

Overview

The purpose of this study is to evaluate the efficacy of Parecoxib and Ketorolac as a preemptive analgesia in patients undergoing lumbar spinal fusion.

A prospective, double-blinded randomized control trial. Randomly allocated patient undergoing posterior lumbar spinal fusion into 3 groups (n=32) to receive Parecoxib, Ketorolac and Placebo around 30 minutes prior to incised skin. Efficacy was assessed by visual analog scale score (0-10), total opioid consumption, complication and bleeding also recorded.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

SUPPORTIVE_CARE

Masking

TRIPLE

Enrollment

Conditions

Postoperative Pain

Interventions

ParecoxibDRUG

Parecoxib 40 mg intravenous

KetorolacDRUG

Ketorolac 30 mg intravenous

Eligibility

Sex: ALLMin age: 18 YearsMax age: 80 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patients undergoing lumbar spinal fusion for one to three levels * ASA class I or II Exclusion Criteria: * History of allergy to Sulfa group * History of allergy to OPOID or NSAIDs * Contraindicate to NSAIDs use * History of coagulopathy or platelet disfunction

Locations (1)

Faculty of Medicine, Prince of Songkla University

Hadyai, Sonkla, Thailand

Outcomes

Primary Outcomes

Pain score

recorded as Verbal Numerical Rating Scare 0-10

Time frame: Postoperative time up to 24 hours

Secondary Outcomes

Total amount of opioid consumption postoperatively

Time frame: Postoperative 24 hours

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.